TechnoPhage

What TechnoPhage does

TechnoPhage, S.A. is a Lisbon-headquartered, privately held clinical-stage biopharmaceutical company founded in 2005 that develops biological and chemical therapeutics across three proprietary platforms spanning infection, neurosciences, and ophthalmology. The company's core technology combines bacteriophage-based biologics, antibody fragment discovery, and a proprietary zebrafish drug screening platform used to repurpose FDA-approved small molecules. Its lead asset, TP-102, is a five-phage cocktail targeting Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii in infected diabetic foot ulcers; TP-102 received FDA Fast Track Designation in May 2021, completed Phase I/IIa in December 2022, completed an 80-patient Phase 2b (REVERSE 2) in December 2025, and is positioned for Phase 3 development. The pipeline is broadened by TP-122 (a phage therapy in Phase 1/2a approved in Europe in June 2026), TZ-161 (a repurposed small molecule in Phase 1b/2a for acute spinal cord injury under the eSpine study since July 2025), TA-201 (a COVID-19 antibody fragment funded by Portugal 2020), and TZ-113 (a Parkinson's dyskinesia program).

TechnoPhage owns and operates an INFARMED-authorized GMP manufacturing facility in Venda Nova, Amadora, one of few in Portugal certified for production of bacteriophages and antibody fragments, and holds 166 live patents across 25 jurisdictions. The company is part of the Technophage Group alongside VectorB2B (a 2019 collaborative drug discovery and contract research platform) and LX Bio – Pharmaceuticals (a 2021 spin-off focused on late-phase clinical trials, production, and commercialization, with a new €40–60M facility planned).

The company is pre-revenue and finances operations primarily through non-dilutive Portuguese public funding, including a €500K Portugal 2020/FEDER grant in 2020 and a €5,442,437.19 PRR grant in 2022 as part of the €35M Bio-Hub consortium. Its go-to-market combines enterprise sales to clinical trial sites and hospital systems across the US, India, Israel, Portugal, and the Netherlands with strategic co-development partnerships (notably the January 2025 PHAXIAM collaboration for Individualized Phage Therapies) and contract GMP manufacturing services for third parties. Future revenue is expected to derive from product commercialization of TP-102, TP-122, and TZ-161 upon regulatory approval, supplemented by licensing royalties and CRO/contract manufacturing income.

Name

TechnoPhage

Legal name

TechnoPhage, SA

Website

https://technophage.pt

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

TechnoPhage is a Lisbon-based clinical-stage biopharmaceutical company developing bacteriophage cocktails, antibody fragments, and repurposed small molecules across infection, neuroscience, and ophthalmology indications, with lead asset TP-102 advancing toward Phase 3.

Ownership category

akta.pro rank

Headquarters

HQ city

Lisbon

HQ country

Portugal

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Biopharmaceutical Development and Commercialization: TechnoPhage develops proprietary biopharmaceutical products (TP-102, TP-122, TZ-161) through clinical trials with the aim of commercializing them upon regulatory approval. Revenue will be generated through product sales targeting diabetic foot infections, spinal cord injuries, and antimicrobial-resistant infections.
2. Contract Manufacturing Services (GMP): TechnoPhage offers GMP manufacturing services to other national and international companies. The company has INFARMED-certified manufacturing facilities for biologics production including bacteriophages and antibody fragments.
3. Collaborative R&D and Licensing: TechnoPhage receives funding through PRR (Recovery and Resilience Plan) grants and collaborates with partners for drug development, receiving compensation for research services and technology licensing.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

TechnoPhage is a clinical-stage biopharmaceutical company developing bacteriophage-based therapeutics, antibody fragments, and repurposed small molecules for infections, neurological disorders, and ophthalmology. Its lead asset TP-102 is a five-phage cocktail for diabetic foot ulcers with FDA Fast Track designation, supported by an in-house INFARMED-certified GMP plant that also offers contract manufacturing for biologics.

Product overview

TechnoPhage is a clinical-stage biopharmaceutical company that develops biological and chemical products using three proprietary technology platforms for infection, neurosciences, and ophthalmology therapeutic areas. The company's core product pipeline includes TP-102 (bacteriophage cocktail for infected diabetic foot ulcers), TP-122 (bacteriophage product in Phase 1/2a), and TZ-161 (repurposed small molecule for spinal cord injury in Phase 1b/2a). Additional pipeline products include TA-201 (COVID-19 therapeutic antibody) and TZ-113 (Parkinson's disease therapy). TechnoPhage operates its own GMP-certified manufacturing plant specializing in biologics production including bacteriophages and antibody fragments, with subsidiary LX Bio handling industrialization and VectorB2B providing integrated drug discovery and development services. The company has a portfolio of 166 live patents across 25 jurisdictions.

Differentiator

Problem solved

Functional benefit

Products and services

• TP-102 Bacteriophage Cocktail Lead clinical asset consisting of five bacteriophages for topical treatment of infected diabetic foot ulcers caused by Pseudomonas aeruginosa, Staphylococcus aureus, and Acinetobacter baumannii; FDA Fast Track designation, Phase I/IIa and Phase 2b completed.
• TP-122 Bacteriophage Product Bacteriophage therapeutic product for treatment of severe resistant infections; regulatory approval received to initiate Phase 1/2a clinical study TP-122_101A in Europe (Portugal and Netherlands).
• TZ-161 Spinal Cord Injury Treatment Repurposed approved small molecule identified through TechnoPhage's zebrafish screening platform for treatment of acute spinal cord injury; currently in Phase 1b/2a (eSpine) study in Spain and Portugal.
• TA-201 COVID-19 Therapeutic Antibody Neutralizing antibody fragment identified from blood samples of COVID-19 patients, designed for administration via nebulization for COVID-19 treatment.
• TZ-113 Parkinson's Disease Program Repurposing project targeting levodopa-induced dyskinesia during OFF periods in Parkinson's patients; US patent application No. 15/568,655 allowed.
• GMP Manufacturing Services GMP-certified contract manufacturing of biologics including bacteriophages and antibody fragments at the Venda Nova, Amadora plant, authorized by INFARMED for manufacture and analysis of medicines for clinical trial use.

Quantifiable outcome

• TP-102 Phase I/IIa demonstrated safety and tolerability with no adverse events reported; reduced bacterial load in infected ulcers and showed wound healing potential
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

13 partnerships are on record, tiered core and minor.

• PHAXIAM TherapeuticscoreStrategic or Co-development Partner · 30 January 2025Strategic collaboration on Individualized Phages Therapies (IPT) combining GMP phage portfolios. Partnership aims to achieve 25 GMP phages by end of 2025 and 35-40 by end of 2026, targeting at least seven critical pathogens including Staphylococcus aureus, Pseudomonas aeruginosa, E. coli, Klebsiella pneumoniae, and Acinetobacter baumannii.
• JSS Medical ResearchcoreImplementation/ SI/ Consulting Partner · 19 January 2025CRO responsible for managing TP-102 REVERSE 2 clinical trial in India. Collaboration with Principal Investigators from various clinical trial sites.
• University of MacauminorStrategic or Co-development Partner · 21 April 2023Collaboration since 2014 on C1 bioactive compound development. Professor Simon Lee presented efficacy data while Technophage focused on manufacturing process, analytical data, toxicology study and regulatory perspective for novel food ingredient derived from Chinese plant.
• LX Bio – PharmaceuticalscoreStrategic or Co-development Partner · 25 July 2022Co-promoter of Bio-Hub National R&D Platform for Production, Commercialization and Distribution of Innovative Biopharmaceuticals. LX Bio leads the consortium aiming to expand development of biological medicines, conduct late-phase clinical trials, and implement global marketing and distribution from Portugal. €19M incentive out of €35M total investment.
• VectorB2B – Drug DevelopingcoreStrategic or Co-development Partner · 25 July 2022Co-promoter of Bio-Hub consortium, providing drug development platform that gathers academic and industrial capacities in health biotechnology. Transforms capacities into viable economical assets through integrated services in drug discovery, project design, contract research and manufacturing.
• Faculty of Pharmacy, University of Lisbon (FFUL)coreStrategic or Co-development Partner · 25 July 2022Co-promoter of Bio-Hub consortium providing academic research capabilities and expertise in pharmaceutical sciences for the development of innovative biological medicines.
• ICNAS (Instituto de Ciências Nucleares Aplicadas à Saúde)coreStrategic or Co-development Partner · 5 May 2021Collaboration on Alzheimer's Disease diagnostic solution in PET imaging. ICNAS contributes expertise in development of radiochemicals including First in Human studies, combined with Technophage's antibody discovery and GMP production capabilities.
• Medinfar GroupcoreStrategic or Co-development Partner · 15 October 2020Collaboration on COVID-19 therapeutic antibody (TA-201) development. Medinfar Group and Recipharm Venture Fund partnership for developing and validating new commercial biomarker for imaging beta-amyloid for early diagnosis of Alzheimer's Disease.
• Johnson & Johnson Innovation, JLABSminorStrategic or Co-development Partner · 1 January 2020Technophage is a resident company of JLABS, a premier life science incubator program. Global network of open innovation ecosystems enabling and empowering innovators to create and accelerate delivery of life-enhancing health and wellness solutions.
• Instituto de Medicina Molecular João Lobo Antunes (iMM)minorStrategic or Co-development Partner · 19 July 2019Collaboration with team led by Leonor Saúde on zebrafish screening platform development for drug discovery and selection for spinal cord injuries. Published in Scientific Reports journal.
• BEAM AllianceminorStrategic or Co-development Partner · 30 June 2015TechnoPhage is a Founding Member of BEAM Alliance, the alliance of Biotech's of Europe innovating in Anti-Microbial Resistance.
• Faculty of Veterinary Medicine, University of LisbonminorStrategic or Co-development Partner · 5 May 2015Signed collaboration agreement for joint research and development activities in veterinary biotechnology applications.
• BialminorStrategic or Co-development Partner · 17 April 2015Research collaboration on antibodies for Alzheimer's disease with Instituto de Medicina Molecular and Bial. Research featured in news article.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Intralytix: U.S.-based biotechnology company developing bacteriophage-based products for bacterial control in human health, food safety, and animal health. Comparable as a phage-product developer with manufacturing capabilities and a multi-application platform analogous to TechnoPhage's three therapeutic pillars.
• PHAXIAM Therapeutics: French clinical-stage biopharmaceutical company (formerly Pherecydes Pharma) focused on phage therapy for resistant bacterial infections. Directly comparable as a phage therapy specialist and an active TechnoPhage partner via the January 2025 strategic collaboration on Individualized Phage Therapies.
• Armata Pharmaceuticals: U.S. clinical-stage biotechnology company developing purified bacteriophage therapies for antibiotic-resistant infections (including Staphylococcus aureus bacteremia and Pseudomonas aeruginosa lung infections). Directly comparable as a phage-therapy pure-play competing in overlapping indications.
• Adaptive Phage Therapeutics: U.S. clinical-stage company developing personalized phage therapy with a focus on individualized matching of phages to patient-specific pathogens. Directly comparable through its individualized phage therapy model targeting resistant infections, similar in mechanism to the PHAXIAM-TechnoPhage partnership strategy.
• Locus Biosciences: U.S. clinical-stage biotechnology company developing engineered phage therapies (crispr-enhanced precision phage products) targeting antibiotic-resistant infections. Directly comparable as a phage-therapy developer overlapping with TechnoPhage's infection indications.

Others

• Hovione: Portuguese-founded contract development and manufacturing organization (CDMO) specialized in active pharmaceutical ingredients and inhaled drug delivery. Comparable as a Lisbon-headquartered biopharmaceutical manufacturing and drug-delivery company, providing ecosystem context for the Portuguese biopharma sector in which TechnoPhage operates.

Emerging players

• Eligo Bioscience: French biotech developing engineered phage-derived particles (eligobiotics) for microbiome precision editing, including acne and antimicrobial-resistant infections. Comparable as a next-generation phage-platform company addressing similar resistant-infection use cases with a differentiated delivery technology.
• ContraFect Corporation: U.S. clinical-stage biotechnology company developing lysin-based and direct lytic agents against drug-resistant bacterial pathogens. Comparable as an anti-infective biological platform targeting resistant infections through a non-traditional antibiotic mechanism.

Regional players

• Bial — Portela & Cª, S.A. Privately held Portuguese pharmaceutical company with a CNS-focused portfolio and active Alzheimer's research partnerships. Comparable as a Portuguese biopharma operating in overlapping geographies and central nervous system indications (TechnoPhage's TZ-113/TZ-161).
• Medinfar Group: Portuguese pharmaceutical group partnering with TechnoPhage on COVID-19 antibody (TA-201) and Alzheimer's biomarker development. Comparable as a domestic pharma partner operating in the same Iberian innovation ecosystem and a current TechnoPhage collaborator.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/technophage-sa
• Xx.com/atechnophage

Compliance15 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TechnoPhage